

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA MEDICAL SYSTEM HOLDINGS LIMITED
康哲藥業控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 867)

Voluntary and Business Update Announcement

**Neurelis Announces the Submission of New Drug Application with FDA For VALTOCO
Nasal Spray (NRL-1)**

Reference is made to the announcement of China Medical System Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 20 August 2018 (the “**Announcement**”) related to the asset purchase of the pharmaceutical preparation, formulation, dosage form, or delivery vehicle, containing or comprising NRL-1 etc. and/or line extensions. NRL-1 (intranasal diazepam) is a proprietary formulation of diazepam, delivered via a nasal formulation in a spray, being developed for the management of pediatric and adult patients who require intermittent use of diazepam to control bouts of increased seizure activity, also known as acute repetitive or cluster seizures. Unless the context otherwise requires, terms defined in the Announcement have the same meanings when used in this announcement.

Neurelis announced that it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for VALTOCO™ (diazepam nasal spray) as a treatment for epilepsy patients six years and older who experience bouts of increased seizure activity, also known as acute repetitive or cluster seizures. Earlier this year, FDA provided conditional acceptance for use of the name “VALTOCO” for the product previously referred to in clinical development as “NRL-1”. For details, please refer to the website of Neurelis (<https://www.neurelis.com/neurelis-news/neurelis-files-new-drug-application-fda-valtocotm-nasal-spray-investigational-treatment-pediatric>), the contents of which do not form part of this announcement.

The Group will prepare for the regulatory application and other related work of VALTOCO in China after Neurelis submits the NDA with FDA for it.

Shareholders and investors are advised to exercise caution in dealing in the shares and other securities of the Company.

By order of the Board
China Medical System Holdings Limited
Lam Kong
Chairman

Hong Kong, 26 September 2018

As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong, Mr. Chen Hongbing and Ms. Chen Yanling as executive directors; and (ii) Mr. Cheung Kam Shing, Terry, Mr. Wu Chi Keung and Mr. Leung Chong Shun as independent non-executive directors.